Zolmitriptan
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Zolmitriptan: Atrophoderma vermiculata
One-Sentence Summary
Zolmitriptan is a 5-HT1B/1D receptor agonist (a triptan), originally used for the acute treatment of migraine. Triptans have also traditionally been cautioned against in brainstem-type aura, so this prediction should be treated as a research question rather than a ready-to-use indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist with both central and peripheral activity. Preclinical work indicates it can inhibit trigeminovascular activation both centrally and peripherally, and it is already established for the acute treatment of migraine with or without aura. The data compiled for this report do not include a detailed mechanism-of-action entry, so this description is drawn from the literature.
Migraine with brainstem aura is a subtype of migraine with aura. It shares core pathophysiology with other migraine types, namely trigeminovascular activation, CGRP release and cortical spreading depression. This makes a mechanistic link plausible.
However, there is an important caveat. Triptans have traditionally been cautioned against, or contraindicated, in brainstem (basilar-type) aura and hemiplegic migraine because of the theoretical risk of vasoconstriction. No study specific to this subtype was found, so the supporting evidence is indirect, drawn from general migraine and migraine-with-aura literature. The high TxGNN score reflects model prediction and should not be read as clinical proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications below studies migraine with brainstem aura directly. They cover zolmitriptan in migraine generally, or triptans in migraine with aura.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review | Headache | American Headache Society updated evidence assessment of acute migraine pharmacotherapies in adults |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | Placebo-controlled trials show zolmitriptan has good 2-hour response and pain-free rates; also improves nausea, photophobia and phonophobia |
| 10473025 | 1999 | Review | Drugs | Oral zolmitriptan 2.5 and 5 mg has rapid onset (significant relief at 45 minutes) and is significantly more effective than placebo |
| 25916333 | 2015 | Review (meta-analysis) | J Headache Pain | Compares frovatriptan with rizatriptan, zolmitriptan and almotriptan in migraine with aura; notes triptans are probably not efficacious if taken during the aura phase |
| 22644173 | 2012 | Subgroup analysis of RCT | Neurol Sci | Frovatriptan vs zolmitriptan 2.5 mg in 18 patients with migraine with aura (small subset of a double-blind crossover study) |
| 9399012 | 1997 | Preclinical | Cephalalgia | Zolmitriptan is a 5-HT1B/1D partial agonist that inhibits trigeminovascular activation centrally and peripherally |
| 17177580 | 2007 | Post-marketing surveillance | Clin Drug Investig | Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray in real-life practice |
| 12864759 | 2003 | Clinical study | Headache | Transcranial Doppler blood-flow velocity in migraine attacks before and after oral zolmitriptan or sumatriptan |
| 22298171 | 2012 | Case report | Cardiol J | Case of zolmitriptan-induced acute myocardial infarction in a 45-year-old woman |
| 25538676 | 2014 | Review | Front Neurol | Treatment options in vestibular migraine; specialised trials are scarce |
India Market Information
The approved indication text is not available for these registrations.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 247965 | Zolitas ODS 5 Strip | Strip of 1 disintegrating strip | Intas Pharmaceuticals Ltd |
| 247573 | Zolitas ODS 2.5 Strip | Strip of 1 disintegrating strip | Intas Pharmaceuticals Ltd |
| 246606 | Zolmist Nasal Spray | Bottle of 7 MDI nasal spray | Cipla Ltd |
| 248233 | Zolpax Nasal Spray | Packet of 5 ml nasal spray | Alteus Biogenics Pvt Ltd |
| 248664 | Zolmit 2.5mg Capsule | Strip of 10 capsules | Admit Pharmaceuticals Pvt Ltd |
A sixth registration, Zolvent Nasal Spray (No. 250377, Chemo Healthcare Pvt Ltd), is also valid. All 6 registrations are single-ingredient products and none has been cancelled.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): The drug is linked to contraindications in a broad set of conditions, mainly cardiovascular and cerebrovascular:
- Hypertension and hypertensive disorder
- Coronary artery disease, myocardial infarction, coronary thrombosis, myocardial ischemia and Prinzmetal angina
- Stroke, transient ischemic attack, cerebral infarction, brain ischemia, cerebrovascular disorder, vertebrobasilar insufficiency and intracranial arteriosclerosis
- Peripheral vascular and arterial disease, intermittent claudication and Raynaud disease
- Wolff-Parkinson-White syndrome and ischemic bowel disease
- Kidney disease, liver disease, gallbladder disease, pyoureter and hemoglobinopathy
- Familial or sporadic hemiplegic migraine
Vertebrobasilar insufficiency and hemiplegic migraine are particularly relevant to the predicted brainstem-aura indication.
- Cardiac risk signal: The literature includes a case report of zolmitriptan-associated acute myocardial infarction, consistent with the vasoconstrictive concern.
- Drug Interactions: 82 interactions were identified. Major-level interactions include:
- Serotonergic and related agents: lorcaserin, fenfluramine, dexfenfluramine, sibutramine
- 5-HT3 antagonists: ondansetron, granisetron, dolasetron, palonosetron
Moderate-level interactions include morphine (including liposomal), cimetidine and obeticholic acid.
Package insert warnings and contraindications for the Indian products were not available. Please refer to the package insert for label safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The theoretical vasoconstrictive risk, the established caution about triptans in this subtype and the knowledge-graph contraindication for hemiplegic migraine and vertebrobasilar insufficiency make this a research question rather than a candidate for clinical development at present.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Indian products (a blocking gap for safety screening)
- Detailed mechanism-of-action data from DrugBank
- A dedicated safety review of triptan use in brainstem aura, including the basis for existing cautions
- Any subtype-specific clinical or observational data on triptans in brainstem aura
- Clarification of the approved indication text for the Indian registrations
Other predictions: Atrophoderma vermiculata (score 0.9990) and ulerythema ophryogenesis (score 0.9983) have no trials, no literature and no plausible mechanistic link to 5-HT1B/1D agonism. Both remain at Evidence Level L5 with a Hold decision.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.